HEALTH

Alzheimer’s drug lecanemab receives accelerated approval amid safety concerns

Jan 6, 2023, 1:27 PM
The US Food and Drug Administration granted accelerated approval Friday for the Alzheimer's disease...
FILE: A sign for the Food And Drug Administration is seen outside of the headquarters on July 20, 2020 in White Oak, Maryland. (Sarah Silbiger, Getty Images)
(Sarah Silbiger, Getty Images)
Originally Published: 06 JAN 23 14:24 ET
Updated: 06 JAN 23 14:43 ET

(CNN) — The US Food and Drug Administration granted accelerated approval Friday for the Alzheimer’s disease drug lecanemab, one of the first experimental dementia drugs to appear to slow the progression of cognitive decline.

“Alzheimer’s disease immeasurably incapacitates the lives of those who suffer from it and has devastating effects on their loved ones,” Dr. Billy Dunn, director of the Office of Neuroscience in the FDA’s Center for Drug Evaluation and Research, said in a statement. “This treatment option is the latest therapy to target and affect the underlying disease process of Alzheimer’s, instead of only treating the symptoms of the disease.”

The Utah Angle: Across the U.S. and in Utah, dementia on the rise in adults

Lecanemab will be marketed as Leqembi, the FDA statement said. It has shown “potential” as an Alzheimer’s disease treatment by appearing to slow progression, according to Phase 3 trial results, but it has raised safety concerns due to its association with certain serious adverse events, including brain swelling and bleeding.

In July, the FDA accepted Eisai’s Biologics License Application for lecanemab under the accelerated approval pathway and granted the drug priority review, according to the company. The accelerated approval program allows for earlier approval of medications that treat serious conditions and “fill an unmet medical need” while the drugs continue to be studied in larger and longer trials.

If those trials confirm that the drug provides a clinical benefit, the FDA could grant traditional approval. But if the confirmatory trial does not show benefit, the FDA has the regulatory procedures that could lead to taking the drug off the market.

What is known about lecanemab

Lecanemab, a monoclonal antibody, is not a cure but works by binding to amyloid beta, a hallmark of Alzheimer’s disease. In late November, results from an 18-month Phase 3 clinical trial published in The New England Journal of Medicine showed that lecanemab “reduced markers of amyloid in early Alzheimer’s disease and resulted in moderately less decline on measures of cognition and function than placebo at 18 months but was associated with adverse events.”

The results also showed that about 6.9% of the trial participants given lecanemab, as an intravenous infusion, discontinued the trial due to adverse events, compared with 2.9% of those given a placebo. Overall, there were serious adverse events in 14% of the lecanemab group and 11.3% of the placebo group.

The Utah Angle: Holiday gift guide for people with Alzheimer’s and their caregivers

The most common adverse events in the lecanemab group were reactions to the intravenous infusions and abnormalities on their MRIs, such as brain swelling and bleeding called amyloid-related imaging abnormalities, or ARIA, which can become life-threatening.

Some people who get ARIA may not have symptoms, but it can occasionally lead to hospitalization or lasting impairment. And the frequency of ARIA appeared to be higher in people who had a gene called APOE4, which can raise the risk of Alzheimer’s disease or other dementias. ARIA “were numerically less common” among APOE4 noncarriers, the study showed.

The drug’s prescribing information carries a warning about ARIA, the FDA says.

The trial results also showed that about 0.7% of participants in the lecanemab group and 0.8% of those in the placebo group died, corresponding to six deaths in the lecanemab group and seven in the placebo group.

Leading up to the FDA decision, some advocacy groups, including the Alzheimer’s Association, were pushing for accelerated approval of lecanemab.

“We believe, based on the totality of positive data from clinical trials of this treatment, that the FDA should approve. Peer-reviewed, published results show lecanemab will provide patients in the earliest stages of Alzheimer’s more time to participate in daily life and live independently. It could mean many months more of recognizing their spouse, children and grandchildren,” Maria Carrillo, the group’s chief science officer, said in a statement days before the FDA decision.

She added that the Alzheimer’s Association hopes that the Centers for Medicare and Medicaid Services “will move quickly” to cover the drug and “revise its coverage decision that currently blocks access to this treatment.” CMS determines whether to cover FDA-approved therapies based on whether it deems them to be safe and effective. Carrillo said that the Alzheimer’s Association “has filed a formal request asking CMS to provide full and unrestricted coverage for FDA-approved Alzheimer’s treatments.”

In 2021, the FDA approved the drug Aduhelm for early phases of Alzheimer’s disease — but that FDA decision has been shrouded in controversy as a congressional investigation found last week that the FDA’s “atypical collaboration” to approve the high-priced Alzheimer’s drug was “rife with irregularities.”

Before Aduhelm, the FDA had not approved a novel therapy for the condition since 2003.

More than 6.5 million people in the United States live with Alzheimer’s disease, according to the Alzheimer’s Association, and that number is expected to grow to 13.8 million by 2060.

‘This drug is not for everyone’

The FDA’s accelerated approval was expected, said Dr. Richard Isaacson, director of the Alzheimer’s Prevention Clinic in the Center for Brain Health at Florida Atlantic University’s Schmidt College of Medicine.

Isaacson said lecanemab can be “another tool” in his toolbox to fight Alzheimer’s disease.

“I will prescribe this drug in the right person, at the right dose and in a very carefully monitored way, but this drug is not for everyone,” he said.

“I would do genetic testing for APOE4 first, and have a frank discussion with my patients,” he said. “If someone is having side effects, if someone is on a blood-thinning medication, if someone has a problem, they need to discuss this with the treating physician, and they need to seek medical attention immediately.”

The-CNN-Wire
™ & © 2023 Cable News Network, Inc., a Warner Bros. Discovery Company. All rights reserved.

We want to hear from you.

Have a story idea or tip? Send it to the KSL NewsRadio team here.

Today’s Top Stories

Health

The Utah House has advanced the bill that bans transgender-related surgeries on minors and pauses t...
Aimee Cobabe

Equality Utah supports bill clarifying rules for therapists when it comes to conversion therapy for minors

Equality Utah is supporting a bill adjusting rules for therapists when it comes to conversion therapy for minors.
1 day ago
When inversions bring pollution to the ground, we breathe it in. That makes it easier to get sick a...
Dale Spaulding

Is illness or poor air quality causing that cough?

Inversion can impact a person's health. Is that why people are coughing, or is it just the regular cold and flu season?
1 day ago
A woman wearing white sitting in front of a light box...
Michelle Lee

Winter blues: light therapy and lifestyle changes can help

SALT LAKE CITY – With the chilly weather and the shorter days, many people are prone to experience the winter blues. In the latest Let’s Get Moving with Maria podcast episode, host Maria Shilaos spoke with Dr. Jason Hunziker from the Huntsman Mental Health Institute about ways people can overcome the winter blues. Seasonal depression […]
2 days ago
A new study finds that reports of bad weather and air actually decrease ridership on the UTA....
Devin Oldroyd

Relief from inversion and poor air quality may be in Utah’s near future

The Beehive State is in the middle of some thick inversion and poor air quality, but relief may be on the way according to the National Weather Service.
4 days ago
A study by Intermountain Health that spanned 40 years and sought answers about the health of people...
Simone Seikaly

Intermountain’s 40-year study provides insight into weight-loss surgery

In some cases the results from the weight-loss surgery study were expected. But at least one result could be a cause for alarm and caution.
4 days ago
The U.S. Department of Agriculture's Food Safety and Inspection Service has issued a recall for mil...
Simone Seikaly

Check your pantry, a Conagra canned meat recall may affect you

Millions of pounds of canned meat and poultry products (mainly Vienna sausages) are involved in the Conagra recall.
4 days ago

Sponsored Articles

Skier being towed by a rider on a horse. Skijoring....
Bear Lake Convention and Visitors Bureau

Looking for a New Winter Activity? Try Skijoring in Bear Lake

This article about skijoring is sponsored by the Bear Lake Convention & Visitors Bureau. Participate in Skijoring the Bear on February 20th, 2023.  What is skijoring? Skijoring is when someone on skis is pulled by a horse, dog, animal, or motor vehicle. The driver leads the skiers through an obstacle course over jumps, hoops, and […]
Banner with Cervical Cancer Awareness Realistic Ribbon...
Intermountain Health

Five Common Causes of Cervical Cancer – and What You Can Do to Lower Your Risk

January is National Cervical Cancer Awareness month and cancer experts at Intermountain Health are working to educate women about cervical cancer, the tests that can warn women about potential cancer, and the importance of vaccination.
Kid holding a cisco fish at winterfest...
Bear Lake Convention and Visitors Bureau

Get Ready for Fun at the 2023 Bear Lake Monster Winterfest

The Bear Lake Monster Winterfest is an annual weekend event jam-packed full of fun activities the whole family can enjoy. This year the event will be held from January 27-29 at the Utah Bear Lake State Park Marina and Sunrise Resort and Event Center in Garden City, Utah. 
happy friends with sparklers at christmas dinner...
Macey's

15 Easy Christmas Dinner Ideas

We’ve scoured the web for you and narrowed down a few of our favorite Christmas dinner ideas to make your planning easy. Choose from the dishes we’ve highlighted to plan your meal or start brainstorming your own meal plan a couple of weeks before to make sure you have time to shop and prepare.
Spicy Homemade Loaded Taters Tots...
Macey's

5 Game Day Snacks for the Whole Family (with recipes!)

Try these game day snacks to make watching football at home with your family feel like a special occasion. 
Happy joyful smiling casual satisfied woman learning and communicates in sign language online using...
Sorenson

The Best Tools for Deaf and Hard-of-Hearing Workplace Success

Here are some of the best resources to make your workplace work better for Deaf and hard-of-hearing employees.
Alzheimer’s drug lecanemab receives accelerated approval amid safety concerns